Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study

INTRODUCTION: Patients with active rheumatoid arthritis who had failed at least one disease-modifying anti-rheumatic drug (DMARD) were treated with adalimumab (ADA) in the ReAct study with the option to continue treatment for 5 years in ReAlise. The purpose of this study was to evaluate the long-ter...

Descripción completa

Detalles Bibliográficos
Autores principales: Burmester, Gerd R, Matucci-Cerinic, Marco, Mariette, Xavier, Navarro-Blasco, Francisco, Kary, Sonja, Unnebrink, Kristina, Kupper, Hartmut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979145/
https://www.ncbi.nlm.nih.gov/pubmed/24460746
http://dx.doi.org/10.1186/ar4452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979145/
https://www.ncbi.nlm.nih.gov/pubmed/24460746
http://dx.doi.org/10.1186/ar4452

Ejemplares similares